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CLINICAL RESEARCH ARTICLE OPEN
Clinical trial of laronidase in Hurler syndrome after
hematopoietic cell transplantation
Lynda E. Polgreen1,2, Troy C. Lund1, Elizabeth Braunlin1, Jakub Tolar1, Bradley S. Miller1, Ellen Fung3, Chester B. Whitley1,
Julie B. Eisengart1, Elise Northrop4, Kyle Rudser4, Weston P. Miller1,5 and Paul J. Orchard1
BACKGROUND: Mucopolysaccharidosis I (MPS IH) is a lysosomal storage disease treated with hematopoietic cell transplantation
(HCT) because it stabilizes cognitive deterioration, but is insufficient to alleviate all somatic manifestations. Intravenous laronidase
improves somatic burden in attenuated MPS I. It is unknown whether laronidase can improve somatic disease following HCT in MPS
IH. The objective of this study was to evaluate the effects of laronidase on somatic outcomes of patients with MPS IH previously
treated with HCT.
METHODS: This 2-year open-label pilot study of laronidase included ten patients (age 5–13 years) who were at least 2 years post-
HCT and donor engrafted. Outcomes were assessed semi-annually and compared to historic controls.
RESULTS: The two youngest participants had a statistically significant improvement in growth compared to controls. Development
of persistent high-titer anti-drug antibodies (ADA) was associated with poorer 6-min walk test (6MWT) performance; when patients
with high ADA titers were excluded, there was a significant improvement in the 6MWT in the remaining seven patients.
CONCLUSIONS: Laronidase seemed to improve growth in participants <8 years old, and 6MWT performance in participants
without ADA. Given the small number of patients treated in this pilot study, additional study is needed before definitive conclusions
can be made.
Pediatric Research (2020) 87:104–111; https://doi.org/10.1038/s41390-019-0541-2
INTRODUCTION
The mucopolysaccharidoses (MPS) are a group of diseases
resulting from specific lysosomal enzyme deficiencies that result
in accumulation of glycosaminoglycans. Debilitating disease-
related pathology is a significant problem that persists even
following standard treatment for Hurler syndrome, the severe
form of mucopolysaccharidosis type I (MPS IH). Hurler syndrome
is the most severe form of alpha-L-iduronidase (IDUA) deficiency
and is characterized by progressive multisystem involvement
including severe cognitive, cardiac, pulmonary, and orthopedic
complications. Most untreated children with MPS IH die from
cardiopulmonary disease by late childhood. The standard of care
for MPS IH, hematopoietic cell transplantation (HCT), has been
successful in decreasing mortality from cardiac, pulmonary
disease, and preserving central nervous system (CNS) func-
tion.1,2 Consequently, children with MPS IH treated with HCT are
living into adulthood.2,3 HCT does not, however, adequately
treat all disease manifestations in MPS IH. Even in the setting of
complete hematopoietic engraftment from enzyme-normal
donors, patients with MPS IH treated with HCT are continuing
to develop severe orthopedic disease, which may include carpal
tunnel syndrome, progressive kyphosis, scoliosis, hip dysplasia,
genu valgum, cervical instability, and cord compression, along
with cardiomyopathy and valve disease, corneal clouding, sleep
disordered breathing, hearing loss, and endocrinological dis-
ease.3–9 Thus, there is an urgent need for augmentative
treatments in patients with MPS IH, despite “successful”
transplantation.
Engraftment of allogeneic hematopoietic cells provides a low
level of continuous enzyme delivery within tissue and plasma
compartments. In contrast, weekly IV laronidase, with a short half-
life ranging from 1.5 to 3.6 h (Package Insert), provides inter-
mittent supraphysiologic plasma levels of enzyme. Therefore, each
treatment approach has different pharmacokinetics. Enzyme
replacement therapy (ERT; (laronidase)) is approved for patients
with MPS I, as this therapy is effective in the treatment of most of
the somatic manifestations of the disease; however, it does not
treat the CNS pathology and is associated with poorer long-term
survival for patients with Hurler syndrome.10 ERT is routinely used
in infants awaiting HCT in order to improve clinical status prior to
HCT and prevent pulmonary complications during HCT,11 but HCT
remains the standard treatment for MPS IH because it can stabilize
cognition and prevent progressive, unrecoverable developmental
deterioration.3,12–22 Administration of laronidase for 8–14 weeks
before and shortly following HCT appears to improve IQ, along
with nonverbal problem solving and processing at 2 years post-
HCT.16 In addition, a retrospective, multicenter, long-term follow-
up study of 217 patients with MPS IH after treatment with HCT
found that a below normal post-HCT IDUA leukocyte enzyme level
is associated with increased morbidity, including more progres-
sion of cord compression, cervical instability, hip dysplasia, carpal
tunnel, overnight hypoxia, and corneal clouding.3 Finally, in a
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murine model of MPS IH, the delivery of supraphysiologic IDUA
following transplantation with lentiviral-mediated genetically
corrected hematopoietic stem cells resulted in improved appear-
ance of the bone and epiphysis, suggesting a dose effect of
enzyme in modifying orthopedic-related outcomes.23 Therefore,
we hypothesized that the addition of intermittent supraphysiolo-
gic dosing of laronidase may benefit patients with MPS IH after
HCT. If laronidase, continued after HCT, prevented complications
of this disease, this has the potential to significantly improve the
lives of affected patients and their families, and may decrease the
risk of medical and surgical interventions required to manage
disease-related complications. The primary objective of this pilot
study was to evaluate safety and tolerability of weekly IV
laronidase in patients with MPS IH treated with HCT at least 2
years prior. Secondary objectives evaluated the effect of weekly IV
laronidase on joint range-of-motion (ROM), muscle strength,
fitness, cardiac findings, and physical activity level.
METHODS
Patients and screening
Inclusion criteria included patients diagnosed with MPS IH that
were <14 years old at study enrollment. Eligible patients must
have been treated with HCT > 2 years prior to study enrollment
and had >10% donor engraftment. Exclusion criteria included
previous administration of laronidase within 2 years, anticipated
survival less than 2 years, or history of cardiac or pulmonary
insufficiency defined by an ejection fraction <40% or requiring
continuous supplemental oxygen, respectively. Subjects were
enrolled between June 2012 and February 2014 at the University
of Minnesota.
For height and ROM outcomes, the study cohort was compared
against historic MPS IH control data from a 9-year longitudinal
observational study.24–26 Inclusion criteria for the longitudinal
study were biochemical and/or genetic diagnosis of MPS IH, age
≥5 years old and <18 years old. Exclusion criteria included
concurrent enrollment in a therapeutic drug trial. All of the
patients from this control cohort had previously undergone HCT.
The historical controls were selected by having MPS IH, history of
HCT, and with comparable age at entry into the study.
Informed consent was obtained from all parents/guardians and
assent was obtained from subjects when appropriate. The
University of Minnesota Human Subjects Committee approved
the protocol for this pilot study. The prior observational study was
conducted at three sites: Los Angeles Biomedical Research
Institute, the University of Minnesota, and Children’s Hospital
Oakland Research Center, and was approved by the Human
Subjects Committee at each of these institutions. This study was
registered on clinicaltrials.gov (NCT 01173016).
Design
This was an open-label, single arm, 2-year, pilot study of weekly
laronidase in subjects with MPS IH who were treated with HCT > 2
years prior to study enrollment. Subjects received weekly
laronidase (0.58 mg/kg i.v.) and were monitored for infusion-
related toxicities by their local treating physician. The local
physicians completed a laronidase administration report form at
the time of each infusion and returned the logs to the study
coordinators at least every 3 months. Donor hematopoietic
chimerism was measured at baseline and every 6 months for
the duration of the 2-year study. Antidrug antibodies (ADA) were
measured by two methods27,28; inhibitory capacity was measured
at ADA titer peak and end-of-study as previously described.28
Subjects were labeled ADA+ if their maximum titer was ≥4000
(using either method) and the mean inhibition (averaged between
the inhibition at the ADA titer peak and the end of the study) was
≥30% as previously described.28 Measurements of ROM, muscle
strength, fitness, physical activity, and growth were also
conducted at baseline and every 6 months. In addition, annualized
growth velocity at baseline was calculated using the most recent
height measurement obtained in clinical practice, but at least
6 months prior to the baseline visit, in seven of ten participants
(data unavailable in three participants).
Outcome measures
The primary outcome measure was safety and tolerability.
Secondary outcome measures included changes from baseline
in several key domains. Bilateral shoulder flexion, elbow
extension, and hip extension were measured using goniometry
and the sites were chosen based on common areas of MPS-
related disease. Muscle strength was measured by a Biodex
System 3 dynamometer (Biodex medical Systems, Inc., Shirley,
NY). The angular velocities of 90 and 120 degrees/second (d/s)
were chosen based on previously reported deficits in these
strength measures in MPS IH.24 Handgrip strength was
measured three times in both hands with a mechanical hand-
held dynamometer with the subject in a seated position at each
visit; the average for each hand is presented. Fitness was
measured by peak oxygen uptake (VO2 peak), peak heart rate
(HR), and time to fatigue during a modified Balke Treadmill
Test.29 This test is recommended for unfit and/or chronically ill
children or adolescents. Briefly, patients began walking at 2.0
mph with a 2% increase in grade every 2 min. A 12-lead
electrocardiogram was monitored continuously throughout the
test for the determination of heart rate and dysrhythmias or
ischemic changes. Heart rate was measured at the end of each
stage (i.e. every 2 min) and time to fatigue (i.e. patient request to
stop despite encouragement to continue) was recorded. VO2
peak was measured by collection and analysis of expired air by a
MedGraphics CPX/D Metabolic System. The 6MWT was con-
ducted as previously described.30 In brief, a 30 m hospital
corridor marked by colored tape at each end was used. Subjects
were instructed to walk from end to end at their self-selected
pace, while attempting to cover as much distance as possible in
the 6 min. The patients were instructed to walk around the mark
as they changed direction. The time and distance covered was
recorded, as was the heart rate prior to and immediately after
completion of the walk test. The 6MWT has previously been
used in assessments of laronidase and other ERT interventions in
patients with lysosomal storage diseases as a measure of overall
physical function and health status.31–33 The 6MWT is a measure
of overall physical function and health status because perfor-
mance of this test incorporates multiple body systems. The
ability to understand and follow the instructions for the test
requires a degree of cognitive ability. The physical performance
of the test is a measure of mobility and coordination as well as
cardiorespiratory status. As such, this test assesses many
functions required to perform typical activities of daily living.
Anthropometric measurements (standing height, sitting height,
and arm span) were performed in triplicate and the average
taken at the baseline and month 24 visits. Height standard
deviation scores (SDS) were calculated based on CDC growth
charts.34 Cardiac ultrasounds were obtained at baseline and
month 24. Two-dimensional imaging was obtained for determi-
nation of anatomy. Left ventricular chamber dimensions and
wall thicknesses were measured by M-mode and shortening
fraction (SF [normal > 27%]) was calculated by standard meth-
odology.35 Pulse-wave and color Doppler interrogation of
cardiac valves was performed for determination of valve
regurgitation or stenosis. To compare chamber dimensions
and wall thicknesses sequentially in a single subject or between
subjects of different sizes, Z-scores based upon body surface
area were calculated.35 A Z-score of 0 represents the normal, or
average, value at a given body surface area and Z-scores
between −2 and +2 are values within 2 standard deviations (SD)
of normal (parameterz.com).
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Statistical analysis
Data are presented in both a descriptive and quantitative fashion
due to the small sample size of this pilot study. The sample size
was chosen based on feasibility given the small population size
from which to recruit. Linear mixed models with random intercept
were used to test for difference in the change in outcome over
time between the treated group and the historic control group. An
additional identical analysis was performed restricted to treated
and control participants under 8 years of age. Linear regression
was used to test for associations of age at study entry with change
in each outcome, and logistic regression for differences in
response by anti-ERT antibody status. Female participants with a
bone age >14 years and males with a bone age >16 years during
the study were excluded from the growth analysis due to near
closure of growth plates. All analyses and graphing were
performed with the use of Prism 7 (GraphPad Software, Inc.), R
v3.4.0,36 and STATA 14. Outcomes are reported as change from
the earliest study visit to the last study visit with a minimum of
12 months between measurements. All analyses were pre-
specified, except the test for associations between outcomes
and age at study entry, which was formally assessed after the
initial review of the study results.
RESULTS
Study participants
Eleven participants (60% male) were enrolled and followed in the
study from June 2012 to April 2016. One withdrew at month 6 at
parents’ request and the remaining ten completed the study.
Baseline characteristics for these ten are described in Table 1. The
rate of adherence to the schedule of weekly infusions of
laronidase in each patient ranged from 79 to 100% (median=
99%). There were no reported drug-related severe adverse events.
There were 23 historical controls who were 48% male (n= 11)
with mean age of 9.3 ± 3.5 years (mean age in treated group was
9.2 ± 2.8 years). At the time of enrollment, the historic control
group was on average 8.0 ± 3.6 years from HCT (7.6 ± 3.5 years
from HCT for treated group). The average age at HCT was 15.4 ±
8.2 months in controls and 19.7 ± 12.7 months in the treated
group. 39% vs. 50% received ERT peri-HCT in controls versus
treated group, respectively. None were treated with ERT at the
time of enrollment in either study.
Efficacy outcomes
Due to missing data, outcome comparisons were preferentially
made from baseline to 24 months, but if baseline and/or 24-
month data were not available, the longest interval between
measurements was reported, with a minimum requirement of
12 months. Missing data are indicated in each table.
Growth. Change in growth velocity was determined by calculat-
ing the difference between baseline and month 24 growth
velocities. Baseline growth velocity was calculated using the most
recent measure done in clinical practice prior to study enrollment
(median 322 days prior [range 188−489 days]), which was
available in six of ten participants. One female participant was
excluded from the within-group growth analyses due to a bone
age of 14.5 years (i.e. closed growth plates). Change in growth
velocity was −1.1 ± 3.8 cm/yr (range −7.0 cm/yr to +4.0 cm/yr).
There was no statistically significant difference in comparison of
the entire cohort in annualized growth velocity in treated patients
versus historic controls (Fig. 1). However, the two participants
under age 8 years old had a significant improvement in
annualized growth velocity compared to 12 controls with the
same age restriction (2.4 cm/yr; 95% CI 0.8−3.9 cm/yr; p= 0.002).
This is supported by the fact that a younger age at study entry was
associated with a better change in height (adjusted for age and
sex) over the study (−0.17 SDS/year; 95% CI −0.34 to −0.01 SDS/
year; p= 0.04]).
Fitness and 6MWT. For peak HR on the treadmill testing, the
average change over 12–24 months was +23 ± 18 bpm (range −7
to +44 bpm). The average change in time to fatigue was 6.2 ± 5.0
min (range −0.8 to 17.2 min), and the average improvement in
6MWT over 18–24 months was 50 ± 92m (range −104 to+264 m).
Within the entire group, there was no significant association of
change in 6MWT or time on treadmill with age at study entry.
Range of motion. Four of ten participants had improvements
(defined for all joints as >5°) in left or right shoulder ROM, 3/10
had improvements in left or right elbow ROM, and 5/10 had
improvements in left or right hip ROM (Table 2). Change in ROM
was not different from historic controls (Fig. 1) and was not
associated with age at study entry.
Muscle strength. Change in handgrip strength was +1.1 ± 1.9 kg
(range −0.7 to 4.0 kg). There was no change in dominant leg
muscle strength measured as peak torque per 100 lbs at 90 and
120 s. Neither change in handgrip strength nor in dominant leg
muscle strength was associated with age at study entry.
Cardiac. Eight of ten subjects had both baseline and month 24
echo data. All had left ventricular end-diastolic diameters,
posterior wall and septal thicknesses within 2 SD of normal and
Table 1. Baseline characteristics of participants
Pt# Prior ERT? Sex Age HCT (m) HCT graft Age study entry (y) ADA (titer) IDUA Chim (% donor) Doses missed
1 No F 8 URD 13 0 WNL 79 0
2 Yes M 33 UCB 5 0 WNL 99 1
3 Yes F 35 UCB 5 400 50% of NL 77 0
4 Yes M 16 UCB 8 100 WNL 81 11
5a No F 2 UCB 10 0 WNL 72 6
6a No M 32 RD 13 0 60% of NL 90 6
7 No M 9 UCB 11 0 WNL 100 1
8 Yes F 24 RD 10 0 50% of NL 100 1
9 No M 31 RD 8 100 WNL 100 0
10a Yes M 7 RD 9 0 WNL 100 0
Pt participant, ERT enzyme replacement therapy, HCT hematopoietic cell transplantation, m months, y years, ADA antidrug antibodies at time of enrollment,
IDUA iduronidase levels, Chim Chimerism, URD unrelated donor, UCB unrelated cord blood
aDeveloped high and persistent antidrug antibodies and neutralizing antibodies during the study
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normal systolic cardiac function as evidenced by shortening
fraction ([SF] mean 38%, range 34–52%). Measures of chamber
dimensions, posterior and septal wall thicknesses, remained within
2 SD of normal for the duration of the study except for one subject
whose left ventricular end-diastolic dimension increased from+1.9
to+3.2 SD and septal wall thickness from 0.4 to 2.6 SD; cardiac
function remained normal at month 24 in all eight subjects (SF
baseline= 38 ± 6.2%; SF month 24= 37 ± 4%; p= 0.57). Of note,
the subject who had an increase in left ventricular end-diastolic
dimension and septal wall thickness also had the highest degree
of mitral dysfunction within the series at baseline and the
shortening fraction was hyper-dynamic (52%) at baseline, but
normalized (39%) at month 24.
At baseline, mitral regurgitation was absent or trace/trivial in six
subjects, mild in one and moderate in the eighth subject. Aortic
regurgitation was absent or trace/trivial in five subjects and mild
in three subjects. Aortic regurgitation tended to increase with
increasing age. Neither mitral nor aortic stenosis was identified.
For the eight subjects with both baseline and month 24 echo data,
mitral regurgitation was unchanged in seven of eight subjects and
increased from none to trivial in one subject over the course of the
study. Aortic regurgitation was unchanged in five subjects but
increased by one or more levels in three subjects (none to mild (1);
none to trace/trivial (1); mild to moderate (1)).
Impact of anti-laronidase antibody status on outcomes. Three
participants (ID5, ID6, and ID10) developed persistently high
antidrug antibody titers with neutralizing antibodies during the
study (ADA+), with 40–98% uptake inhibition, that persisted for
the duration of the study. Recognizing that antibody production
may affect functional outcomes, we analyzed outcomes related to
the presence (ADA+) or absence of persistent high neutralizing
antibody titers (ADA−). Rate of change in all outcomes adjusted
for age at enrollment and antibody status are shown in Table 3.
The only clinically significant effect of ADA+status identified was a
decrease in the 6MWT in comparison to the ADA− patients (−14
m; 95% CI: −28 to −1m; p= 0.038 [Fig. 2]). And, when ADA+
patients were removed from the analysis, the ADA− group had
a significant improvement in 6MWT over the study (82 m; 95% CI:
2−161 m; p= 0.045).
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Fig. 1 Comparison of change in a height and b−d range of motion in treated participants compared to historic MPS IH control data. Blue
connected circles indicate participants who did not develop high antidrug antibodies during the study. Red connected squares indicate
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Global outcome assessment. A heatmap indicating a positive
response in green, no response in black, and a negative response
in red is included to provide a global response to treatment
(Fig. 3). Outcome-specific changes used to define each incre-
mental change in the heatmap color are detailed in Figure 3 as
well.
DISCUSSION
This study evaluated ERT augmentation in a post-HCT population
with MPS IH. We found that ERT, 2 or more years after HCT in MPS
IH, was safe and tolerable (rate of adherence to the schedule of
weekly infusions of laronidase ranged from 79 to 100%). There
was an improvement in growth velocity in the two youngest
participants compared to historic controls, and an improvement in
the 6MWT in participants who did not develop high, persistent,
neutralizing antidrug antibodies. Cardiac echo parameters
remained mostly unchanged throughout the study but mild
progression of aortic valve regurgitation was seen in ~40% of
subjects.
Severe limitations in joint ROM is present in most patients with
MPS IH despite successful engraftment after HCT. In a prior study
of such patients, an improvement from pre-HCT to post-HCT in
knees, hips, and elbow ROM in 38–63% of patients followed over
an average of 6.4 years after HCT was found.37 Our historic data on
transplanted children with MPS IH who did not undergo long-term
ERT augmentation indicate that shoulder flexion, elbow extension,
and hip extension deteriorate slowly over time (Fig. 1). In the
attenuated form of MPS I (MPS IA), joint stiffness improves with
laronidase treatment but is not entirely alleviated.31,38,39 The
longest study of joint outcomes in patients with MPS I has been in
MPS IA where it is reported that after the same duration of therapy
as our study (2 years) the average improvement in shoulder
flexion on ERT was 29° (range 5°−50°).39 For MPS IH ROM after
HCT, we know of only one publication on ROM response to a
treatment besides HCT. In that publication, a patient with MPS IH
was treated with adalimumab, an antiinflammatory medication
used for juvenile idiopathic arthritis, for 16 weeks. There was a
response in shoulder flexion of 20° and 49°, seen in the left and
right shoulders respectively.40 We found much more variability
than either of these studies. In our study the range of change in
shoulder flexion was −44° to +72° over 2 years. This is likely
related to the high degree of variability in the severity of joint
disease in patients with MPS IH after HCT, and was similar in
regards to our observances in elbow extension.
We obtained two measures of fitness during our study: the
modified Balke treadmill test and the 6MWT. The measurement of
peak oxygen uptake during treadmill testing is considered the
best single physiologic indicator of an individual’s cardiopulmon-
ary fitness and can also be used to monitor changes in
cardiopulmonary fitness over time.29,41 Unfortunately, our partici-
pants were rarely able to tolerate the mask necessary for this
measurement during the treadmill test, and so this outcome
proved not feasible. They were, however, able to perform the
6MWT, on which MPS IA participants have previously shown
improvements of 19.7 ± 68.6 m over 26 weeks32 and 31.7 ± 10.2 m
over 2 years of laronidase ERT.31 We found a mean increase on the
6MWT that was 2.5 and 1.6 times these prior studies, but also had
greater variability: 50 ± 92m. The variability in response to therapy
is likely due to a broad spectrum of physical impairment in MPS IH
patients after HCT, other interventions such as surgical proce-
dures, and variation in motivation.
Prior reports of ADA following IV laronidase found a high
incidence of the development of ADA that appear to have a
negative impact of biochemical measures of disease activity.28,42,43
For example, in one study of MPS IH patients treated before and
during HCT, 50% of patients developed ADA with both catalytic
Table 2. Change in passive joint range-of-motion (ROM) over 12−24 months
Outcomes Change over 12–24 months
Mean ± SD
(range)
>5° improvement in ROM
N/Total (%)
>5° worsening in ROM
N/Total (%)
Shoulder flexion—left, ° 8 ± 33 (−44 to 72)2 4/8 (40) 3/8 (30)
Shoulder flexion—right, ° 5 ± 24 (−32 to 36)2 4/8 (40) 3/8 (30)
Elbow extension—left, ° 3 ± 9 (−12 to 16)5 3/5 (30) 1/5 (10)
Elbow extension—right, ° −1 ± 5 (−9 to 10)5 1/5 (10) 1/5 (10)
Hip extension—left, ° 1 ± 14 (−15 to 22)2 4/8 (40) 3/8 (30)
Hip extension—right, ° 0 ± 14 (−25 to 17)2 5/8 (50) 3/8 (30)
Superscript numbers indicated # missing data for either baseline or month 24 visit. Percent with improvement or worsening in ROM is calculated based on
total number with available data
Table 3. Comparison of rates of change after adjusting for age at
enrollment for outcomes in participants who developed antibodies
compared to those who did not
Outcome N obs,
N
ADA+ minus ADA−
(95% CI)
p value
6MWT, m 46, 10 −14.35 (−27.91, −0.79) 0.038
Left shoulder flexion, ° 45, 10 1.11 (0.14, 2.07) 0.024
Right shoulder flexion, ° 45, 10 1.06 (−0.08, 2.19) 0.068
Left elbow extension, ° 41, 10 0.07 (−0.43, 0.57) 0.779
Right elbow extension, ° 41, 10 0.01 (−0.48, 0.51) 0.959
Left hip extension, ° 46, 10 0.28 (−0.39, 0.96) 0.407
Right hip extension, ° 46, 10 0.56 (−0.19, 1.31) 0.144
Max HR treadmill, bpm 43, 10 0.16 (−0.79, 1.11) 0.744
Time on treadmill, min 38, 10 −0.11 (−0.43, 0.22) 0.517
Handgrip, kg 45, 10 0.01 (−0.18, 0.19) 0.944
Peak torque at 90°/s, Ft-lbs/
100 lbs
38, 10 −0.27 (−0.82, 0.27) 0.322
Peak torque at 120°/s, Ft-
lbs/100 lbs
38, 10 −0.16 (−0.66, 0.33) 0.524
Sitting height, cm 37, 10 −0.07 (−0.18, 0.04) 0.195
Arm span, cm 38, 10 −0.06 (−0.35, 0.23) 0.680
Standing height, cm 40, 10 0.01 (−0.18, 0.21) 0.884
Height SDS 40, 10 0.00 (−0.02, 0.03) 0.904
A negative coefficient means antibody positive participants had a more
negative change in the outcome after adjustment for age at enrollment
compared to antibody negative participants
Statistically significant p-values are bold <0.05
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enzyme inhibition and uptake inhibition of catalytically active
enzyme, but became immune tolerant 26–137 days after HCT.42
However, there was a negative impact of ADA on the ratio of
dermatan sulfate to chondroitin sulfate in the six patients
studied.42 Others have found that laronidase ADA correlate with
worse sleep disordered breathing.28 In our study, patients who did
not develop high ADA had a significant improvement in their
6MWT over the course of the study; however, patients with ADA
did not improve on their 6MWT. This clinical outcome data seems
to support previously published data on the negative impact of
ADA on biochemical outcomes. However, the question remains as
to whether patients with MPS IH treated with ERT after HCT will
become immune tolerant over time, as has been reported,39,42 or
whether ADA persist and negate the positive impact of enzyme
secreted by donor cells.
Progressively worsening short stature has been reported by
us and others in patients with MPS IH after HCT.3,5 On average,
after HCT patients with MPS IH lose approximately 0.5 height
SDS every 2 years; however, this varies slightly with age and
post-HCT leukocyte IDUA levels.3,5 Five of our participants had a
change in height SDS of better than the expected loss of 0.5
SDS every 2 years, and three of our study patients had a positive
increase in height SDS of 0.1, 0.4, and 0.7. The improvement in
annualized growth velocity in our treated group versus historic
controls was 0.9 cm/yr (95% CI: −0.4 to 2.2 cm/yr; p= 0.16), with
the greatest increase in comparative growth velocity in the
youngest two participants (Fig. 1). The clinical significance of
these improvements is unclear based on the limited sample
size, but suggests that additional study would be useful to
determine if this finding is observed in a larger group of
younger patients.
Cardiac echo structural and functional parameters were within
normal limits in all subjects and cardiac valve regurgitation was
absent or trivial in most subjects at the initiation of ERT. The
structural and functional parameters remained normal after
24 months of ERT in all except one subject who began the study
with moderate mitral regurgitation. Progression of aortic valve
regurgitation has previously been reported as a long-term finding
in MPS I patients after both HCT44 and enzyme replacement
therapy.45
Although this study was primarily designed to understand
safety and tolerability, the small sample size, which is an inherent
limitation in rare disease research, restricts the number of factors
that can be controlled when modeling outcomes, therefore
requiring a conservative approach in drawing definitive conclu-
sions. It is also possible that, given the small sample size, a longer
study is needed to see statistically significant, and clinically
meaningful, improvements in outcomes in this small group. Our
study highlights the challenges in measuring the impact of
disease burden in this pediatric population due to a variety of
reasons, such as an inability to understand test directions,
maintenance of motivation, and other factors such as disease
and/or surgeries. For instance, we determined that assessment of
cardiopulmonary fitness (VO2 peak from the Modified Balke
Treadmill test) was not feasible in our cohort due to an inability to
wear the required mask while walking on the treadmill. Despite
these limitations, this study provides (1) valuable insight into how
a future study should be designed, considering the physical and
cognitive limitations of the population, and (2) pilot data to
adequately power a future study in order to draw definitive
conclusions about the effects of laronidase in patients with MPS IH
after HCT.
In conclusion, enzyme augmentation with laronidase 0.58 mg
i.v. weekly is well tolerated in posttransplantation MPS IH patients.
However, we cannot make conclusions on the usefulness of ERT in
patients with MPS IH after HCT at this time due to the limitations
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described above. Additional testing is needed. One concerning
finding however, is that we observed the development of antidrug
antibodies in several patients, which was not anticipated, as the
hematopoietic cells of these patients are endogenously producing
enzyme. In addition, there is a suggestion that antibody
generation may be clinically important, as an improvement was
noted in the 6MWT in the individuals who did not develop high
ADA levels. An improvement in growth rates were also seen, but
only for the younger participants. If enzyme is used after
transplantation, monitoring patients for the development of
antibody would be important, as at least in the case of the
6MWT, it may be clinically relevant.
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